INIFY Laboratories AB

kr 5.65As of Sun 8 Nov 2026, 12:00 UTC

OSL:INIFYHealthcare

Country Norway

PE (Fwd) —

TSR 4Y CAGR (7.54%)

Div yield —

ROE (59.65%)

Diagnostics & Research

Beta (5Y) —

PE TTM —

TSR TTM (3.42%)

Mkt cap kr 607.2M

ROIC (125.36%)

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

kr 6.02

6.53%

(63.89%)

Price above Reference Value

TTM

FYE 31 Dec NOK

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

23.01

Revenuekr M

—

1.193

13.13

22.01

29.78

329.49%

—

Revenue growth%

—

1000.67

67.59

35.34

534.13

—

84.92

Gross margin%

—

71.42

85.68

84.54

84.35

84.54

—

(370.29)

Operating margin%

—

(4673.85)

(403.51)

(316.54)

(100.00)

(403.51)

—

(363.58)

Net margin%

—

(4469.82)

(393.29)

(308.49)

(100.00)

(393.29)

—

P/E ratio (avg)x

—

EV/EBITx

—

FCF yield (avg)%

—

(13.93)

(29.22)

(8.49)

(21.57)

—

FCF margin%

—

(366.83)

(476.89)

(100.00)

(421.86)

—

FCF / Net incomex

—

0.933

1.546

—

1.239

—

(125.36)

ROIC%

—

(392.86)

(425.38)

(233.26)

(29.68)

(392.86)

—

(59.65)

Return on equity%

—

(62.70)

(87.20)

(97.02)

(21.82)

(87.20)

—

(53.41)

Return on assets%

—

(57.34)

(120.37)

(48.30)

(20.09)

(57.34)

—

(0.78)

EPSkr

—

(1.16)

(1.14)

(1.09)

(0.48)

—

EPS growth%

—

1.61

4.20

56.13

2.90

—

1.30

Bookvalue per shkr

—

1.85

0.74

1.72

2.14

(3.69%)

—

FCF per sharekr

—

(1.06)

(1.69)

(0.48)

—

Dividend per shkr

—

Div yield (avg)%

—

Payout ratio%

—

107.5

Shares (diluted)M

—

45.96

45.24

62.07

◌62.07

16.21%

—

Buyback yield%

—

1.57

(37.21)

◌—

(17.82)

—

D/E ratiox

—

549.7

Enterprise valuekr M

—

545.4

323.1

301.7

293.2

(25.63%)

—

LT debtkr M

—

Peers (US$70.48M)

Cap (US$)

SenzaGen AB (publ)

16.27M

—

IDL Diagnostics AB…

7.686M

—

Prostatype Genomics AB…

6.891M

—

BIONET Corp.

69.08M

40.34x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(990.6)

(630.1)

Own earn%

—

Sh yield%

—

(17.82)

Owners

Insiders/Inst%

15.82

4.76

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/3

Revenue growth years

—

EPS growth years

—

Dividend streakyrs

Op margin range%

−4674–−317

$1 testx

—

Incr. ROIC%

−40

INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.

Growth vs revenue

Latest

Trend

2Y CAGR

Rel growth

Revenue

kr 22.01M

329.49%

1.00×

Cost of revenue

kr 3.403M

215.90%

0.54×

Operating expenses

kr 88.26M

24.86%

0.08×

Asset mix

Trend

Other

57.51%

Cash and investments

40.93%

Goodwill & intangibles

1.56%

Reinvestment returns

No breakdown available